Whitehawk Therapeutics (WHWK) Cost of Revenue (2022 - 2025)
Whitehawk Therapeutics' (WHWK) quarterly Cost of Revenue came in at $760000.0 in Q1 2025, up 16.56% year-on-year from $652000.0 in Q1 2024, and down 3.8% on a QoQ basis from $790000.0 in Q4 2024.
Whitehawk Therapeutics (WHWK) Cost of Revenue (2022 - 2025) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 4 years of Cost of Revenue data on file, last reported at $760000.0 in Q1 2025.
- On a quarterly basis, Cost of Revenue rose 16.56% year-over-year to $760000.0 in Q1 2025; TTM through Dec 2025 was $760000.0, a 74.87% decrease from a year earlier, with the FY2025 full-year figure at $760000.0, down 74.87% from the prior year.
- Cost of Revenue for Q1 2025 stood at $760000.0, down from $790000.0 in the prior quarter.
- Over the last five years, Cost of Revenue for WHWK reached as high as $927000.0 in Q4 2023 and fell as low as $179000.0 in Q1 2022.
- Historically, Cost of Revenue has averaged $609846.2 across 4 years, with a median of $656000.0 in 2023.
- Across the five-year window, Cost of Revenue surged 317.57% in 2023 and retreated 14.78% in 2024, its largest moves.
- Year by year, Cost of Revenue stood at $222000.0 in 2022, then soared by 317.57% to $927000.0 in 2023, then slipped by 14.78% to $790000.0 in 2024, then fell by 3.8% to $760000.0 in 2025.
- Per Business Quant data, the three most recent Cost of Revenue figures were $760000.0 in Q1 2025, $790000.0 in Q4 2024, and $804000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Whitehawk Therapeutics | 256.87 Mn | 45.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 760,000.00 |
| Mar 31, 2025 | 760,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Sep 30, 2024 | 804,000.00 |
| Sep 30, 2024 | 804,000.00 |
| Jun 30, 2024 | 778,000.00 |
| Jun 30, 2024 | 778,000.00 |
| Mar 31, 2024 | 652,000.00 |
| Mar 31, 2024 | 652,000.00 |
| Dec 31, 2023 | 927,000.00 |
| Dec 31, 2023 | 927,000.00 |
| Sep 30, 2023 | 697,000.00 |
| Sep 30, 2023 | 697,000.00 |
| Jun 30, 2023 | 656,000.00 |
| Jun 30, 2023 | 656,000.00 |
| Mar 31, 2023 | 529,000.00 |
| Mar 31, 2023 | 529,000.00 |
| Dec 31, 2022 | 222,000.00 |
| Dec 31, 2022 | 222,000.00 |